CapyFin

Loading...

CapyFin Real-time Earnings Reports.

Products

Earnings

Get in Touch

Contact Us
X (Twitter)
LinkedIn

Resources

Privacy Policy
Terms of Service
Sign Up
Sign In

© 2025 CapyFin. All rights reserved.

Disclaimer: This platform provides information and recommendations for educational purposes only and is not a substitute for professional financial advice. Our content covers a range of investment classes, including stocks and cryptocurrencies, and we do not guarantee the completeness, accuracy, reliability, or suitability of this information, which may include data from third-party services and content generated by artificial intelligence (AI). Investing in stocks, cryptocurrencies, and other financial instruments involves risks, including the potential loss of principal. Users should independently verify all information and seek advice from qualified professionals tailored to their individual financial situations and investment objectives. Our content and services are provided "as is" without any warranties, express or implied. We are not liable for any losses or damages arising from the use of our services. This disclaimer is subject to change; users are advised to review it periodically. Usage of our services constitutes acceptance of these terms.

🇺🇸 NASDAQ:OCGN

Overview Earnings Dividends

Feb 25, 2022

•

Dec 31, 2021

Ocugen Q4 2021 Earnings Report

Ocugen experienced a transformational year with significant progress across its portfolio, including the lifting of the clinical hold for COVAXIN™ and advancements in gene therapy clinical development.

Key Takeaways

Ocugen reported fourth quarter and full year 2021 financial results, highlighting the lifting of the clinical hold for COVAXIN™, progress in pediatric EUA submission, initiation of a Phase 1/2 clinical trial for OCU400, and a public offering of common stock.

FDA lifted clinical hold on IND application for COVAXIN™, clearing the way for Phase 2/3 clinical trial.

Engagement with FDA to advance pediatric EUA for COVAXIN™ included submission of safety data and neutralization data against Omicron.

Comprehensive responses regarding COVAXIN™ submitted to Health Canada for the NOD.

OCU400 Phase 1/2 clinical trial initiated for the treatment of inherited retinal diseases.

EPS

-$0.07

Previous year: $0.02

-450.0%

Cash and Equivalents

$95M

Previous year: $24M

+295.0%

Free Cash Flow

-$13M

Previous year: -$4.53M

+186.7%

Total Assets

$106M

Previous year: $27.4M

+286.3%

Ocugen

Ocugen

Forward Guidance

Ocugen is poised for another great year in 2022, with plans to commence clinical trials and provide periodic updates.

Company Overview

Full financial data and analysis